Cargando…

Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience

This systematic study aims at analyzing the differences between the approach of the European healthcare systems to the pharmaceutical market and the American one. This paper highlights the opportunities and the limitations given by the application of managed entry agreements (MEAs) in European count...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciulla, Michele, Marinelli, Lisa, Di Biase, Giuseppe, Cacciatore, Ivana, Santoleri, Fiorenzo, Costantini, Alberto, Dimmito, Marilisa Pia, Di Stefano, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914690/
https://www.ncbi.nlm.nih.gov/pubmed/36767022
http://dx.doi.org/10.3390/healthcare11030447
_version_ 1784885725658873856
author Ciulla, Michele
Marinelli, Lisa
Di Biase, Giuseppe
Cacciatore, Ivana
Santoleri, Fiorenzo
Costantini, Alberto
Dimmito, Marilisa Pia
Di Stefano, Antonio
author_facet Ciulla, Michele
Marinelli, Lisa
Di Biase, Giuseppe
Cacciatore, Ivana
Santoleri, Fiorenzo
Costantini, Alberto
Dimmito, Marilisa Pia
Di Stefano, Antonio
author_sort Ciulla, Michele
collection PubMed
description This systematic study aims at analyzing the differences between the approach of the European healthcare systems to the pharmaceutical market and the American one. This paper highlights the opportunities and the limitations given by the application of managed entry agreements (MEAs) in European countries as opposed to the American market, which does not regulate pharmaceutical prices. Data were collected from the Organisation for Economic Co-operation and Development (OECD), the European Medicines Agency, and the national healthcare agencies of US and European countries. A literature review was undertaken in PubMed, Scopus, MEDLINE, and Google for a period ten years (2010–2019). The period 2020–2021 was considered to compare health expenditure before and after the SARS-CoV-2 pandemic. Scarce information from national agencies has been given in terms of MEAs related to the COVID-19 pandemic. The comparison between the United States approach and the European one shows the importance of a market access regulation to reduce the cost of therapies, increasing the efficiency of national healthcare systems and the advantages in terms of quality and accessibility to the final users: patients. Nevertheless, it seems that the golden age of MEAs for Europe was during the examined period. Except for Italy, countries will move to other forms of reimbursements to obtain higher benefits, reducing the costs of an inefficient implementation and outcomes in the medium term.
format Online
Article
Text
id pubmed-9914690
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99146902023-02-11 Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience Ciulla, Michele Marinelli, Lisa Di Biase, Giuseppe Cacciatore, Ivana Santoleri, Fiorenzo Costantini, Alberto Dimmito, Marilisa Pia Di Stefano, Antonio Healthcare (Basel) Article This systematic study aims at analyzing the differences between the approach of the European healthcare systems to the pharmaceutical market and the American one. This paper highlights the opportunities and the limitations given by the application of managed entry agreements (MEAs) in European countries as opposed to the American market, which does not regulate pharmaceutical prices. Data were collected from the Organisation for Economic Co-operation and Development (OECD), the European Medicines Agency, and the national healthcare agencies of US and European countries. A literature review was undertaken in PubMed, Scopus, MEDLINE, and Google for a period ten years (2010–2019). The period 2020–2021 was considered to compare health expenditure before and after the SARS-CoV-2 pandemic. Scarce information from national agencies has been given in terms of MEAs related to the COVID-19 pandemic. The comparison between the United States approach and the European one shows the importance of a market access regulation to reduce the cost of therapies, increasing the efficiency of national healthcare systems and the advantages in terms of quality and accessibility to the final users: patients. Nevertheless, it seems that the golden age of MEAs for Europe was during the examined period. Except for Italy, countries will move to other forms of reimbursements to obtain higher benefits, reducing the costs of an inefficient implementation and outcomes in the medium term. MDPI 2023-02-03 /pmc/articles/PMC9914690/ /pubmed/36767022 http://dx.doi.org/10.3390/healthcare11030447 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ciulla, Michele
Marinelli, Lisa
Di Biase, Giuseppe
Cacciatore, Ivana
Santoleri, Fiorenzo
Costantini, Alberto
Dimmito, Marilisa Pia
Di Stefano, Antonio
Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
title Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
title_full Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
title_fullStr Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
title_full_unstemmed Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
title_short Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
title_sort healthcare systems across europe and the us: the managed entry agreements experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914690/
https://www.ncbi.nlm.nih.gov/pubmed/36767022
http://dx.doi.org/10.3390/healthcare11030447
work_keys_str_mv AT ciullamichele healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT marinellilisa healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT dibiasegiuseppe healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT cacciatoreivana healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT santolerifiorenzo healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT costantinialberto healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT dimmitomarilisapia healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience
AT distefanoantonio healthcaresystemsacrosseuropeandtheusthemanagedentryagreementsexperience